A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

November 24, 2023

Study Completion Date

November 24, 2023

Conditions
COVID-19 Prevention
Interventions
BIOLOGICAL

Ad26.COV2.S

Participants will receive intramuscular (IM) injection of Ad26.COV2.S.

Trial Locations (18)

1864

Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto

2001

Shandukani Research Centre, Johannesburg

39503

Medpharmics, LLC, Gulfport

68701

Meridian Clinical Research, LLC, Norfolk

77573

Maximos OB/GYN, League City

87102

Medpharmics, LLC, Albuquerque

4534002

Clinical Research College, São Paulo

30130-100

Universidade Federal De Minas Gerais - Hospital das Clínicas, Belo Horizonte

88811-508

Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose, Criciúma

17525-160

Associacaode Ensino de Marilia LTDA - UNIMAR - Universidade de Marilia, Marília

59025-050

Centro de Estudos e Pesquisas em Moléstias Infecciosas - CEPCLIN, Natal

90035-903

Hospital das Clinicas de Porto Alegre, Porto Alegre

90430-001

NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul, Porto Alegre

09715-090

CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo

15090-000

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, São José do Rio Preto

18040-425

CMPC - Consultoria Médica e Pesquisa Clínica, Sorocaba

0485

Ndlovu Elandsdoorn Site, Dennilton

0122

Stanza Clinical Research Centre : Mamelodi, Mamelodi East

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT04765384 - A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) | Biotech Hunter | Biotech Hunter